Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
10x Genomics›
Website
AddedFeb 19, 2024
UpdatedJul 22, 2026
10x Genomics

10x Genomics

Public

10x Genomics: A leading American biotech firm, innovating in gene sequencing since 2012.

HQ
Pleasanton, CA, US
Founded
2012
Loading
Overview
Compare
Fundraising
Employees
Website

10x Genomics - Website

An index of every page on 10xgenomics.com, by section.

32 pages across 7 sections · Updated Jul 21, 2026·

Homepage

10x Genomics's front door: current positioning and top-line messaging.

10xgenomics.com
  • Homepage

Products / ServicesProducts

The products and services as 10x Genomics markets them.

10xgenomics.com/products
  • Xenium Catalyst/products/xenium-catalyst
  • Atera Catalyst/products/atera-catalyst
  • Chromium Analysis/products/chromium-analysis
  • Chromium Compare/products/chromium-compare
  • Cloud Analysis/products/cloud-analysis

Contact

Sales, support, and partnership channels for reaching 10x Genomics directly.

10xgenomics.com/contact
  • Partnership/contact/partnership
  • Amr/contact/sales/amr
  • Apac/contact/sales/apac
  • Emea/contact/sales/emea

AboutCompany

Company story, mission, and background as 10x Genomics tells it.

10xgenomics.com/company
  • Alan Mateo/company/board/alan-mateo
  • Ben Hindson/company/board/ben-hindson
  • John Stuelpnagel/company/board/john-stuelpnagel
  • Kim Popovits/company/board/kim-popovits
  • Sarah Teichmann/company/board/sarah-teichmann

CareersSoftware

Open roles and how 10x Genomics recruits, straight from the source.

10xgenomics.com/careers/software

Blog

Product updates, deep-dives, and company thinking: 10x Genomics's 6-post archive.

10xgenomics.com/blog
  • 10 Things to Know About the Chromium Single Cell Atac Solution
  • 10x at Ashg17 Thursday Wrap Up
  • 10x at Ashg17 Wednesday Wrap Up
  • 10x at Eesomics from Single to Multiomics Applications and Challenges in Data Integration
  • 10x at Eshg 2017/blog/10x-at-eshg-2017

ComparisonChromium Compare

6 comparison pages published by 10x Genomics.

  • Chromium Compare/products/chromium-compare
  • Bulk vs Single Cell Rna Seq Experimental Differences and Advantages of Single Cell Resolution
  • Immunotherapy Impacts Moving the Needle on Pediatric Glioma and Rare Cancers with Single Cell and Spatial Tools
  • Humankidney Nextgem Flex Highlow Input Gem X Flex Comparison
  • Human Pbmcs Next Gem Flex Gem X Flex Comparison
  • Hodgkins Lymphoma Dissociated Tumor Targeted Compare Gene Signature Panel 3 1 Standard 4 0 0